The Truth About Hong Kong, China Listing Fees: Zero Government Charges, Real Costs Elsewhere

1. Key takeaways

The official position is unambiguous: listing under the Medical Device Administrative Control System (MDACS) is entirely free of charge. The government collects no application fee, no assessment fee and no certificate fee. Any budget built around a government fee line is therefore built on a cost that does not exist.

Real cost arises in 3 places instead. The first is the local entity: business registration, maintenance of a Hong Kong, China company and local responsible person services. The second is conformity assessment, which is needed only where route 1 is used, because that route requires assessment by a conformity assessment body. The third is documentation: technical documentation, clinical or performance evaluation, and label localisation. Of the three, only documentation is a common expense across every route.

The consequence for budgeting is that comparisons between quotations are usually invalid, because suppliers quote against different route assumptions. A quotation that appears lower may simply have excluded the conformity assessment step, and one that appears higher may include documentation work that the other assumed the manufacturer already had. Any figure presented without an official source should be treated as a practical estimate rather than as official data.

2. Legal basis

The fee position is stated in the MDD publication Overview of the Medical Device Listing Process in Hong Kong, uploaded on 8 October 2025, under the heading recording that fees are entirely waived. The application and approval process is described in Chapter 5 of GN-01, updated and issued on 1 September 2026. The conformity assessment framework, including the additional conditions mechanism at clause 6.6, is set out in GN-04, Guidance Notes on Conformity Assessment Framework and Conformity Assessment Bodies, also updated and issued on 1 September 2026. The inspection obligation that can generate cost after approval appears in GN-08, Guidance Notes on Listing of Local Manufacturers of Medical Devices, at clause 4.10.

Two details in the legal basis deserve attention because they carry cost implications that applicants do not expect. First, GN-04 clause 6.6 allows additional conditions to be attached in the conformity assessment context, so an approval can impose ongoing obligations even where the assessment itself was straightforward. Second, GN-08 clause 4.10 creates an obligation to cooperate with site inspection covering premises and related storage or transport facilities, which converts some of the cost from a one-off submission into a standing operational requirement.

3. Expert insights

Zero charging is a deliberate policy instrument. The government has repeatedly stated its intention to bring more medical devices into MDACS so as to facilitate the transition to a future statutory regime, and the fee waiver is one of the means by which that is achieved. From that reasoning it follows that fees will most likely be introduced once the regime is placed on a statutory footing, a practical estimate for which no official fee schedule has been published. Budgets that assume permanent zero charging therefore carry an unhedged assumption.

The cost structure differs by route. Route 2, which relies on approval in a reference jurisdiction, avoids the conformity assessment step and concentrates cost in the local entity and in documentation. Route 1, which runs through a conformity assessment body, adds assessment cost on top of both. For a product that already holds a reference jurisdiction approval, the cost advantage of route 2 is material, and the choice of route is consequently the largest single cost decision in the project.

The hidden cost sits in time and opportunity. Assessment takes 12 weeks, acknowledgement takes 2 weeks, and queries during review are unpredictable in number and duration. For a company bidding for public supply, the loss of tender eligibility caused by a listing delay often exceeds the sum of all direct costs, a practical estimate rather than a measured figure. This is the cost item that quotations never show, and the one that most often decides whether a project was worth doing.

Renewal and changes are long-term expenditure. A listing is valid for 5 years, and renewal requires the documentation to be re-assembled and re-confirmed. During the term, changes to design, material or labelling may trigger a variation notification under GN-10. Compliance maintenance across a five-year cycle should be included in the initial budget rather than discovered in year four, because the work arrives whether or not it was planned for.

Why no amount is given here. No official source states a fee for local entity maintenance, conformity assessment or documentation, because those are market prices rather than regulated charges. Any specific number attributed to them would be an assumption dressed as data, and a budget built on such a number is more dangerous than a budget built on a range with a stated basis.

4. Practical recommendations

• Split the budget into three lines. Budget separately for the local entity, conformity assessment and documentation, so that the absence of a government fee does not hide the two largest cost centres behind a single application line.
• Choose route 2 wherever a reference approval exists. Confirming an existing reference jurisdiction approval first, then selecting the route on that finding, removes the conformity assessment cost from the project.
• Price time into the quotation comparison. Work backwards from the tender closing date, and treat scheduling risk as a cost line with an owner rather than as a planning assumption.
• Estimate the full five-year cost. Include renewal work, variation notifications under GN-10 and maintenance of the vigilance system in the initial business case.
• Label every estimate by its source. Mark figures with no official source as a practical estimate, so that internal approvals rest on a stated basis rather than on an implied certainty.

5. Verification checklist

• □ Government fee position confirmed as entirely waived, on the official statement.
• □ Project budget split into local entity, conformity assessment and documentation lines.
• □ Applicable route confirmed and assessment cost estimated accordingly.
• □ Listing schedule risk reflected in the tender plan.
• □ Full five-year cost estimate completed, including renewal and variations.
• □ Every figure without an official source marked as a practical estimate.
• □ Fee position re-checked at each project gate, in case a published schedule appears.

Regulatory information verified as at 29 October 2026 against the official sources listed under legal basis; where those sources are updated, the latest published version prevails.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for Hong Kong, China. Our team coordinates local responsible persons, import and wholesale dealer licensing, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com